Lipids and renal cystic disease.
Schrier
Robert W
RW
Division of Renal Diseases and Hypertension, University of Colorado, Denver CO, USA. robert.schrier@uchsc.edu
Levi
Moshe
M
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004146:Dioxanes / Q000008:administration & dosage* / Q000627:therapeutic use; D000068338:Everolimus; D005919:Glomerular Filtration Rate; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D006801:Humans; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy*; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
C520404:(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide; D000806:Angiotensin-Converting Enzyme Inhibitors; D004146:Dioxanes; D011759:Pyrrolidines; D000068338:Everolimus; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D020123:Sirolimus